|
Pharmacology
Citations 41-50 of 165 total displayed.
|
Past content
(since Dec 2002):
|
- MATTERS ARISING
Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate
- Wouter M. Kooloos, Henk-Jan Guchelaar, Tom W. J. Huizinga, and Judith A. M. Wessels
Rheumatology 2009; 48: 1176-1177.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Possible miliary tuberculosis during adalimumab therapy with negative  -IFN release assays
- Pamela Mangat, Peter Taylor, and Sonya Abraham
Rheumatology 2009; 48: 1177-1178.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate: reply
- Yvonne C. Lee, Jing Cui, Karen H. Costenbader, Nancy A. Shadick, Michael E. Weinblatt, and Elizabeth W. Karlson
Rheumatology 2009; 48: 1177-a.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Possible miliary tuberculosis during adalimumab therapy with negative -IFN release assays: reply
- Alison L. Endean, Simon M. Barry, and Steven A. Young-Min
Rheumatology 2009; 48: 1178.
[Extract]
[Full Text]
- EDITORIALS
Promoting science over serendipity in prescribing anti-TNF therapy
- Meng M. Chee, Nicola Alcorn, Kenneth Paterson, and Rajan Madhok
Rheumatology 2009; 48: 865-866.
[Extract]
[Full Text]
- REVIEWS
Methotrexate, rheumatoid arthritis and infection risk—what is the evidence?
- Andrew McLean-Tooke, Catherine Aldridge, Sheila Waugh, Gavin P. Spickett, and Lesley Kay
Rheumatology 2009; 48: 867-871.
[Abstract]
[Full Text]
- CLINICAL
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases
- Claire Immediato Daïen, Agnes Monnier, Pascal Claudepierre, Arnaud Constantin, Jean-Paul Eschard, Eric Houvenagel, Mahtab Samimi, Stephan Pavy, Edouard Pertuiset, Eric Toussirot, Bernard Combe, and Jacques Morel for the Club Rhumatismes et Inflammation (CRI)
Rheumatology 2009; 48: 883-886.
[Abstract]
[Full Text]
- CLINICAL
Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
- Edmund K. Li, Lai-Shan Tam, Tracy Y. Zhu, Martin Li, Catherine L. Kwok, Tena K. Li, Ying Ying Leung, Kong Chiu Wong, and Cheuk Chun Szeto
Rheumatology 2009; 48: 892-898.
[Abstract]
[Full Text]
- CLINICAL
High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis
- Hans-Rudolf Ziswiler, Daniel Aeberli, Peter M. Villiger, and Burkhard Möller
Rheumatology 2009; 48: 939-943.
[Abstract]
[Full Text]
- CLINICAL
Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression
- Anselm Mak, Alicia A. C. Cheak, Jason Y. S. Tan, Hnin Cho Su, Roger C. M. Ho, and Chak Sing Lau
Rheumatology 2009; 48: 944-952.
[Abstract]
[Full Text]
|
|
